文献速递神经核医学

阿尔茨海默病与额颞叶痴呆中糖代谢改变和Aβ沉积与神经递质系统分布相关

Glucose metabolism alterations and Aβ deposition in AD and FTD are related to the distribution of neurotransmitter systems.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2025-08-07

本回顾性队列纳入507例受试者(261例AD、111例MCI、62例FTD、73例正常对照),采用18F-FDG PET、18F-AV45 Aβ PET和结构MRI多模态神经影像,结合JuSpace工具箱评估影像改变与神经递质受体/转运体分布的空间共定位。AD糖代谢减低与5-羟色胺能、GABA能、多巴胺能及谷氨酸能系统相关,FTD与5-羟色胺能、多巴胺能及阿片受体相关;Aβ沉积在AD与5HT2a、GABAa及NAT共定位,在MCI与D1受体共定位。

要点

  • AD与FTD糖代谢减低分别与不同神经递质系统分布存在空间共定位关系。
  • Aβ沉积在AD与5HT2a、GABAa、NAT共定位,在MCI与D1受体共定位。
  • AD中FDG或Aβ PET-神经递质相关性与MMSE/MoCA评分显著相关。

核心结论

  • AD和FTD在神经递质系统上表现出独特的空间易损性,与糖代谢减低和Aβ病理密切相关。
  • 识别疾病特异性神经影像-神经递质特征可推进生物标志物开发,并支持针对分子通路的靶向治疗策略。

研究设计与样本

  • 本回顾性队列研究纳入507例受试者,包括261例AD、111例MCI、62例FTD和73例正常对照。
  • 受试者接受多模态神经影像检查,包括18F-FDG PET、18F-AV45 Aβ PET和结构MRI。
  • 采用JuSpace工具箱评估影像改变与神经递质受体/转运体分布的空间共定位。
  • 采用Spearman相关评估影像-神经递质共定位与认知评分的关联。
  • 所有分析采用错误发现率(FDR)校正控制P < 0.05。

主要发现

  • AD表现为颞顶叶和额叶区域糖代谢减低,FTD表现为额颞叶区域糖代谢减低。
  • AD糖代谢减低与5-羟色胺能、γ-氨基丁酸能(GABA能)、多巴胺能及谷氨酸能系统相关。
  • FTD糖代谢减低与5-羟色胺能、多巴胺能及阿片受体相关。
  • AD中Aβ沉积与5HT2a受体、γ-氨基丁酸A型(GABAa)受体及去甲肾上腺素转运体(NAT)共定位,MCI中Aβ沉积与D1受体共定位。
  • AD中FDG或Aβ PET-神经递质相关性与MMSE/MoCA评分显著相关;Aβ-5-羟色胺转运体(SERT)或氟多巴(FDOPA)相关性与Aβ阳性MCI的认知下降相关(P < 0.05)。

关键数值与推荐

  • 空间共定位分析显示AD糖代谢减低与5-羟色胺能、GABA能、多巴胺能及谷氨酸能系统相关。
  • FTD糖代谢减低与5-羟色胺能、多巴胺能及阿片受体相关。
  • AD中Aβ沉积与5HT2a受体、GABAa受体及NAT共定位。
  • MCI中Aβ沉积与D1受体共定位。
  • AD中FDG或Aβ PET-神经递质相关性与MMSE/MoCA评分显著相关,Aβ-SERT或FDOPA相关性与Aβ阳性MCI认知下降相关(P < 0.05)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: This study aimed to elucidate the spatial correlations among alterations in glucose metabolism, amyloid-beta (Aβ) deposition, and neurotransmitter systems across Alzheimer's disease (AD), mild cognitive impairment (MCI) and frontotemporal dementia (FTD), while assessing their associations with clinical cognitive decline. METHODS: In this retrospective cohort study, 507 participants (261 AD, 111 MCI, 62 FTD and 73 normal controls) underwent multimodal neuroimaging, including 18F-FDG PET, 18F-AV45 Aβ PET, and structural MRI. Spatial co-localization of imaging alterations with neurotransmitter receptor/transporter distributions was assessed using the JuSpace toolbox. Spearman correlations evaluated associations between imaging-neurotransmitter co-localization and cognitive scores. False discovery rate (FDR) correction was used to control for P < 0.05 for all analyses. RESULTS: AD showed glucose hypometabolism in temporoparietal and frontal regions, while FTD was observed in the frontotemporal areas. Spatial co-localization analyses revealed subtype-specific neurotransmitter vulnerabilities: AD glucose hypometabolism correlated with serotonergic, γ-aminobutyric acidergic (GABAergic), dopaminergic, and glutamatergic systems, while FTD correlated with serotonergic, dopaminergic, and opioid receptors. Aβ deposition co-localized with 5HT2a receptor, γ-aminobutyric acid type A (GABAa) receptors, and noradrenaline transporter (NAT) in AD, as well as D1 receptor in MCI. In AD, FDG or Aβ PET-neurotransmitter correlations significantly associated with MMSE/MoCA scores, while Aβ-serotonin transporter (SERT) or Fluorodopa (FDOPA) correlations linked to cognitive decline in Aβ-positive MCI (P < 0.05). CONCLUSION: This study demonstrates that AD and FTD exhibit unique spatial vulnerabilities in neurotransmitter systems, closely tied to glucose hypometabolism and Aβ pathology. The identification of disease specific neuroimaging-neurotransmitter signatures advances biomarker development and supports targeted therapeutic strategies tailored to molecular pathways. CLINICAL TRIAL NUMBER: not applicable. 1. Decreased glucose metabolism in AD and FTD has spatial localization relationship with different neurotransmitter systems.2. Aβ deposition has a co-localization relationship with 5HT2a, GABAa, NAT, and D1 distribution in AD or MCI.3. In AD, FDG or Aβ PET-neurotransmitter correlations significantly associated with MMSE/MoCA scores, while Aβ PET-SERT or FDOPA correlations linked to cognitive decline in Aβ-positive MCI.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Bi S, Chen Z, Li Y, et al. Glucose metabolism alterations and Aβ deposition in AD and FTD are related to the distribution of neurotransmitter systems. Eur J Nucl Med Mol Imaging. 2025. PMID: 40773016. doi:10.1007/s00259-025-07485-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。